By regulating BAP1-dependent transcriptional signatures, such as ASCL1/MYCL/E2F signaling, our studies highlight the potential to target BAP1’s activity using our next-generation iBAP inhibitor as a novel form of SCLC therapy (Fig. 4I). This evidence concerns the gene MYCL and small cell lung carcinoma.